GLP1_NEW
Exenatide and rosiglitazone injection
EXENROSI_SC
Doses in this pooled treatment
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.19 (-1.78 to -0.59) | 0.77 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.12 (-2.53 to 2.76) | 0.50 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.72 (0.44 to 6.43) | 0.46 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.15 (0.25 to 5.47) | 0.45 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.91 (1.48 to 10.28) | 0.27 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.70 (0.79 to 9.57) | 0.40 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 4.29 (1.28 to 17.60) | 0.14 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.66 (0.42 to 18.47) | 0.29 |